On October 16, 2023 I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, reported that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023, on Monday, October 23 at 12:00 p.m. CET (Press release, I-Mab Biopharma, OCT 16, 2023, View Source [SID1234636027]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Abstract Title:
First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors
Presentation Number:
1039P
Presenter:
Dr. Geoffrey Ku, Memorial Sloan Kettering Cancer Center
Session:
Poster Presentation: Investigational Immunotherapy
Location:
Hall 8, IFEMA Madrid, Spain
Presentation Date/Time:
Monday, October 23, 2023, 12:00 p.m. – 1:00 p.m. Central European Time
The abstract is currently available on the ESMO (Free ESMO Whitepaper) website. Please visit the following link to read the full abstract.
About Givastomig
Givastomig, also known as TJ-CD4B/ABL111, is a bispecific antibody designed to bind to Claudin 18.2 (CLDN 18.2) as a tumor engager and 4-1BB as a conditional T-Cell activator. It binds to tumor cells expressing various levels of CLDN18.2, i.e., gastric cancer and pancreatic cancer cells, and conditionally activates intra-tumoral T cells at the tumor site through the 4-1BB arm. Givastomig appears to effectively maintain a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both CLDN18.2 antibody and 4-1BB antibody while avoiding or minimizing liver toxicity and systemic immunotoxicity commonly seen with 4-1BB antibodies as a drug class. Being developed under collaboration between I-Mab and ABL Bio, a clinical-stage biotechnology company in South Korea, givastomig is currently being investigated in a Phase 1 clinical study in the U.S. and China. In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer, including cancer of the gastroesophageal junction.